Loading…

Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration

Abstract Purpose To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation. Summary The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many...

Full description

Saved in:
Bibliographic Details
Published in:American journal of health-system pharmacy 2021-01, Vol.78 (1), p.60-64
Main Authors: Szewczyk, Michael T, Soefje, Scott A
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c3219-4dd08a44299481e79c8f2c36d4a1d1d4e2c1ff548edf18bdd231caeb821923ec3
container_end_page 64
container_issue 1
container_start_page 60
container_title American journal of health-system pharmacy
container_volume 78
creator Szewczyk, Michael T
Soefje, Scott A
description Abstract Purpose To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation. Summary The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many logistical problems for hospitals and infusion center pharmacies. Due to its short stability, the drug cannot be made ahead of time and coordination with a patient’s arrival at an infusion site is challenging. This becomes exceptionally challenging when a urology clinic has limited compounding capacity and/or is distant from the site of BCG medication preparation. This article describes an innovative process involving use of closed-system transfer devices (CSTDs) to allow for the administration of BCG in a urology clinic offsite from a medical center’s infusion center facilities. Conclusion The use of the CSTD allowed the patients to continue to receive bladder instillations at an offsite urology clinic without significantly disrupting compounding workflow at the small infusion center pharmacy that was the nearest to the clinic.
doi_str_mv 10.1093/ajhp/zxaa339
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2454131383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ajhp/zxaa339</oup_id><sourcerecordid>2454131383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3219-4dd08a44299481e79c8f2c36d4a1d1d4e2c1ff548edf18bdd231caeb821923ec3</originalsourceid><addsrcrecordid>eNp9kM1u1DAUhS0Eoj-wY428o4uG-tqejr2spj8gVWID6-jGvtGkOHFqO9NO34jn4MVINQO7sjp38Z1zpY-xDyA-g7DqDO_W49nTI6JS9hU7hIVaVNIK8Xq-xdJWUhh5wI5yvhMCpBHnb9mBUsICwPKQ4SVtKMSxp6Hw2HIceDcMcYOl2xD3FOZIW563uVDP25h4g64LYcp8haGnUqi6mX7_St3Am4DeU-Lo-27ocknzSBzesTcthkzv93nMflxffV99qW6_3XxdXdxWTkmwlfZeGNRaWqsN0NI600qnzr1G8OA1SQdtu9CGfAum8V4qcEiNmctSkVPH7GS3O6Z4P1Eudd9lRyHgQHHKtdQLDQqUUTN6ukNdijknausxdT2mbQ2ifpZaP0ut91Jn_ON-eWp68v_gvxZnQOyAhxgKpfwzTA-U6jVhKOuXNj_tKnEa___9DzP5lWw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2454131383</pqid></control><display><type>article</type><title>Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>Szewczyk, Michael T ; Soefje, Scott A</creator><creatorcontrib>Szewczyk, Michael T ; Soefje, Scott A</creatorcontrib><description>Abstract Purpose To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation. Summary The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many logistical problems for hospitals and infusion center pharmacies. Due to its short stability, the drug cannot be made ahead of time and coordination with a patient’s arrival at an infusion site is challenging. This becomes exceptionally challenging when a urology clinic has limited compounding capacity and/or is distant from the site of BCG medication preparation. This article describes an innovative process involving use of closed-system transfer devices (CSTDs) to allow for the administration of BCG in a urology clinic offsite from a medical center’s infusion center facilities. Conclusion The use of the CSTD allowed the patients to continue to receive bladder instillations at an offsite urology clinic without significantly disrupting compounding workflow at the small infusion center pharmacy that was the nearest to the clinic.</description><identifier>ISSN: 1079-2082</identifier><identifier>EISSN: 1535-2900</identifier><identifier>DOI: 10.1093/ajhp/zxaa339</identifier><identifier>PMID: 33091117</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>American journal of health-system pharmacy, 2021-01, Vol.78 (1), p.60-64</ispartof><rights>American Society of Health-System Pharmacists 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2020</rights><rights>Copyright Oxford University Press 2020.</rights><rights>American Society of Health-System Pharmacists 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3219-4dd08a44299481e79c8f2c36d4a1d1d4e2c1ff548edf18bdd231caeb821923ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33091117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szewczyk, Michael T</creatorcontrib><creatorcontrib>Soefje, Scott A</creatorcontrib><title>Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration</title><title>American journal of health-system pharmacy</title><addtitle>Am J Health Syst Pharm</addtitle><description>Abstract Purpose To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation. Summary The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many logistical problems for hospitals and infusion center pharmacies. Due to its short stability, the drug cannot be made ahead of time and coordination with a patient’s arrival at an infusion site is challenging. This becomes exceptionally challenging when a urology clinic has limited compounding capacity and/or is distant from the site of BCG medication preparation. This article describes an innovative process involving use of closed-system transfer devices (CSTDs) to allow for the administration of BCG in a urology clinic offsite from a medical center’s infusion center facilities. Conclusion The use of the CSTD allowed the patients to continue to receive bladder instillations at an offsite urology clinic without significantly disrupting compounding workflow at the small infusion center pharmacy that was the nearest to the clinic.</description><issn>1079-2082</issn><issn>1535-2900</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kM1u1DAUhS0Eoj-wY428o4uG-tqejr2spj8gVWID6-jGvtGkOHFqO9NO34jn4MVINQO7sjp38Z1zpY-xDyA-g7DqDO_W49nTI6JS9hU7hIVaVNIK8Xq-xdJWUhh5wI5yvhMCpBHnb9mBUsICwPKQ4SVtKMSxp6Hw2HIceDcMcYOl2xD3FOZIW563uVDP25h4g64LYcp8haGnUqi6mX7_St3Am4DeU-Lo-27ocknzSBzesTcthkzv93nMflxffV99qW6_3XxdXdxWTkmwlfZeGNRaWqsN0NI600qnzr1G8OA1SQdtu9CGfAum8V4qcEiNmctSkVPH7GS3O6Z4P1Eudd9lRyHgQHHKtdQLDQqUUTN6ukNdijknausxdT2mbQ2ifpZaP0ut91Jn_ON-eWp68v_gvxZnQOyAhxgKpfwzTA-U6jVhKOuXNj_tKnEa___9DzP5lWw</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Szewczyk, Michael T</creator><creator>Soefje, Scott A</creator><general>Oxford University Press</general><general>Copyright Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210101</creationdate><title>Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration</title><author>Szewczyk, Michael T ; Soefje, Scott A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3219-4dd08a44299481e79c8f2c36d4a1d1d4e2c1ff548edf18bdd231caeb821923ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szewczyk, Michael T</creatorcontrib><creatorcontrib>Soefje, Scott A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of health-system pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szewczyk, Michael T</au><au>Soefje, Scott A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration</atitle><jtitle>American journal of health-system pharmacy</jtitle><addtitle>Am J Health Syst Pharm</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>78</volume><issue>1</issue><spage>60</spage><epage>64</epage><pages>60-64</pages><issn>1079-2082</issn><eissn>1535-2900</eissn><abstract>Abstract Purpose To describe the development of an innovative process to deliver bacillus Calmette-Guérin (BCG) to an offsite urology clinic for bladder instillation. Summary The use of BCG, a live virus vaccine for treatment of patients with localized cancer of the urinary bladder, has created many logistical problems for hospitals and infusion center pharmacies. Due to its short stability, the drug cannot be made ahead of time and coordination with a patient’s arrival at an infusion site is challenging. This becomes exceptionally challenging when a urology clinic has limited compounding capacity and/or is distant from the site of BCG medication preparation. This article describes an innovative process involving use of closed-system transfer devices (CSTDs) to allow for the administration of BCG in a urology clinic offsite from a medical center’s infusion center facilities. Conclusion The use of the CSTD allowed the patients to continue to receive bladder instillations at an offsite urology clinic without significantly disrupting compounding workflow at the small infusion center pharmacy that was the nearest to the clinic.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>33091117</pmid><doi>10.1093/ajhp/zxaa339</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1079-2082
ispartof American journal of health-system pharmacy, 2021-01, Vol.78 (1), p.60-64
issn 1079-2082
1535-2900
language eng
recordid cdi_proquest_miscellaneous_2454131383
source Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)
title Development of an innovative delivery system for bacillus Calmette-Guérin bladder administration
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A49%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20an%20innovative%20delivery%20system%20for%20bacillus%20Calmette-Gu%C3%A9rin%20bladder%20administration&rft.jtitle=American%20journal%20of%20health-system%20pharmacy&rft.au=Szewczyk,%20Michael%20T&rft.date=2021-01-01&rft.volume=78&rft.issue=1&rft.spage=60&rft.epage=64&rft.pages=60-64&rft.issn=1079-2082&rft.eissn=1535-2900&rft_id=info:doi/10.1093/ajhp/zxaa339&rft_dat=%3Cproquest_cross%3E2454131383%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3219-4dd08a44299481e79c8f2c36d4a1d1d4e2c1ff548edf18bdd231caeb821923ec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2454131383&rft_id=info:pmid/33091117&rft_oup_id=10.1093/ajhp/zxaa339&rfr_iscdi=true